Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Octave Bioscience Inc. operates within the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is assigned to 1 distinct examiner, BOWERS, ERIN M. The focus of the current prosecution is concentrated on this single matter, which allows the applicant to develop a highly specific response to the examiner's concerns.
The data shows that 1 distinct art unit is involved in the review process. BOWERS, ERIN M is the busiest examiner for the portfolio, with 1 busiest examiner pending action. This means that the entire pending docket is currently under the supervision of 1 distinct examiner within 1 distinct art unit.
For a practitioner, having 1 pending office action and 1 distinct examiner simplifies the management of the portfolio. The involvement of only 1 distinct art unit ensures that the examination follows the specific standards of that unit. Since the busiest examiner pending count is 1, there are no other pending matters to coordinate within this portfolio at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWERS, ERIN M | 1 | 54.7% | +9.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024149 | Biomarkers for Predicting Multiple Sclerosis Disease Progression | BOWERS, ERIN M | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18024149 | Biomarkers for Predicting Multiple Sclerosis Disease Progression | BOWERS, ERIN M | 1653 | §101§103§112DP | Non-Final OA | — | Pending | Mar 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOctave Bioscience Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erin M Bowers has the most, with 1 of Octave Bioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
